Regeneron Pharmaceuticals (NASDAQ:REGN) Posts Earnings Results, Beats Expectations By $1.71 EPS

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported $11.49 EPS for the quarter, beating analysts’ consensus estimates of $9.78 by $1.71, MarketWatch Earnings reports. Regeneron Pharmaceuticals had a net margin of 48.06% and a return on equity of 50.10%. The firm had revenue of $2.97 billion during the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter last year, the firm earned $10.09 EPS. The firm’s revenue for the quarter was up 17.2% compared to the same quarter last year.

Regeneron Pharmaceuticals stock traded down $16.32 during mid-day trading on Friday, reaching $623.05. 773,940 shares of the company were exchanged, compared to its average volume of 584,325. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.07 and a current ratio of 4.71. The firm has a market cap of $67.63 billion, a P/E ratio of 8.83, a PEG ratio of 1.19 and a beta of 0.25. The business has a fifty day moving average of $677.84 and a 200 day moving average of $643.39. Regeneron Pharmaceuticals has a 12-month low of $492.13 and a 12-month high of $747.42.

Several research firms have recently issued reports on REGN. Morgan Stanley raised their price objective on Regeneron Pharmaceuticals from $605.00 to $632.00 and gave the company an “equal weight” rating in a research note on Tuesday, April 12th. Cowen increased their target price on shares of Regeneron Pharmaceuticals from $640.00 to $645.00 in a research note on Wednesday, April 20th. BMO Capital Markets reaffirmed a “buy” rating and set a $780.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, February 11th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. Finally, Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $694.00 target price for the company in a research report on Monday, January 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $724.63.

In other Regeneron Pharmaceuticals news, EVP Plew Daniel P. Van sold 6,781 shares of the firm’s stock in a transaction that occurred on Wednesday, February 23rd. The shares were sold at an average price of $613.99, for a total value of $4,163,466.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert E. Landry sold 325 shares of the company’s stock in a transaction on Friday, April 8th. The stock was sold at an average price of $737.79, for a total value of $239,781.75. Following the transaction, the chief financial officer now directly owns 28,744 shares in the company, valued at $21,207,035.76. The disclosure for this sale can be found here. Insiders sold a total of 44,559 shares of company stock worth $30,297,368 over the last quarter. Company insiders own 11.84% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in REGN. Barclays PLC raised its holdings in shares of Regeneron Pharmaceuticals by 54.3% in the fourth quarter. Barclays PLC now owns 489,609 shares of the biopharmaceutical company’s stock worth $309,201,000 after buying an additional 172,347 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in Regeneron Pharmaceuticals by 4.9% during the 4th quarter. Parametric Portfolio Associates LLC now owns 300,877 shares of the biopharmaceutical company’s stock worth $190,010,000 after acquiring an additional 14,185 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Regeneron Pharmaceuticals by 3.1% in the fourth quarter. The Manufacturers Life Insurance Company now owns 201,085 shares of the biopharmaceutical company’s stock valued at $127,956,000 after purchasing an additional 5,969 shares during the period. Penserra Capital Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $2,325,000. Finally, Toroso Investments LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 64.9% during the fourth quarter. Toroso Investments LLC now owns 6,233 shares of the biopharmaceutical company’s stock worth $3,936,000 after purchasing an additional 2,454 shares during the period. 83.83% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals (Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Articles

Earnings History for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.